Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  pegylated liposomal doxorubicin hydrochloride
Find trials that include:  Any drugs shown
Results 1-25 of 27 for your search:
Start Over
Trametinib in Treating Patients with Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer
Status: Active
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 19 and over
Trial IDs: GOG-0281, NCI-2014-00629, NCT02101788
Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients with Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Active
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: NRG-GY005, NCI-2015-00651, NCT02502266
Study for Women With Platinum Resistant Ovarian Cancer Evaluating EC145 in Combination With Doxil® (PROCEED)
Status: Temporarily closed
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: 8109-002, NCI-2011-00940, EC-FV-06, NCT01170650
A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CR100983, NCI-2013-01419, 2012-004808-34, ET743OVC3006, NCT01846611
Clinical Trial of Lurbinectedin (PM01183) in Platinum Resistant Ovarian Cancer Patients
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: PM1183-C-004-14, NCI-2015-01497, NCT02421588
Olaparib or Cediranib Maleate and Olaparib Compared with Standard Platinum-Based Chemotherapy in Treating Patients with Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Health services research, Treatment
Age: Not specified
Trial IDs: NRG-GY004, NCI-2015-00606, NCT02446600
Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for Multiple Myeloma
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: MM08-141, NCI-2012-00848, NCT01177683
Pegylated Liposomal Doxorubicin Hydrochloride and Nintedanib in Treating Patients With Recurrent Epithelial Ovarian, Primary Peritoneal, Fallopian Tube, or Recurrent Metastatic Endometrial Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: GYN10-149, NCI-2012-02106, 1011004095, 1103-09, NCT01485874
Selinexor (KPT-330) and Pegylated Liposomal Doxorubicin Hydrochloride For Relapsed or Refractory Multiple Myeloma
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: MCC 17814, NCI-2014-02019, NCT02186834
Pegylated Liposomal Doxorubicin Hydrochloride and Bevacizumab in Treating Patients with Advanced Kaposi Sarcoma
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 09-C-0130, NCI-2013-01450, 090130, NCT00902239, P09493, NCT00923936
Bortezomib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients with Relapsed or Refractory Acute Myeloid Leukemia
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 to 80
Trial IDs: UCDCC#230, NCI-2014-00564, 322070-12, X05385, NCT01736943
BRCA1 Protein Expression in Patients With Metastatic Breast Cancer Receiving Pegylated Liposomal Doxorubicin Hydrochloride
Status: Active
Phase: Phase II
Type: Treatment
Age: Over 18
Trial IDs: 1300000710, NCI-2013-02365, NCT01990352
Avatar-Directed Chemotherapy in Treating Patients with Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: MC1463, NCI-2014-02399, Mod14-002986-03, NCT02312245
Pegylated Liposomal Doxorubicin Hydrochloride and Carboplatin Followed by Surgery and Paclitaxel in Treating Patients with Triple Negative Stage II-III Breast Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 041401, NCI-2014-02029, NCT02315196
MV-NIS or Investigator's Choice Chemotherapy in Treating Patients with Ovarian, Fallopian, or Peritoneal Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MC1365, NCI-2015-00133, NCT02364713
PH2 Study of IMGN853 vs Investigator's Choice of Chemo in Adults With FRa+ Adv. EOC, Primary Peritoneal or Primary Fallopian Tube Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: IMGN0403, NCI-2016-00320, NCT02631876
Pegylated Liposomal Doxorubicin Hydrochloride, Bevacizumab, and Temsirolimus in Treating Patients With Advanced Cancer
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 12 and over
Trial IDs: 2008-0384, NCI-2012-01665, NCT00761644
Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients with Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 10-01206, NCI-2012-03161, AECM-000248, 8475, 00-0248, NCT01145430
Carboplatin, Pegylated Liposomal Doxorubicin Hydrochloride, and Everolimus in Treating Patients with Relapsed Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 10-019, NCI-2011-00055, ERPGYN067, NCT01281514
Romidepsin and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients with Stage IB-IVB Relapsed or Refractory T-cell Lymphomas
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 112516, NCI-2014-01722, CC#112516, RM-CTCL-PI-0012, UCSF CC# 112516, UCSF Protocol Number 112516, NCT01902225
Ibrutinib, Temozolomide, Etoposide, Pegylated Liposomal Doxorubicin Hydrochloride, Dexamethasone, and Rituximab in Treating Patients with Primary Central Nervous System Lymphoma
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 9577, NCI-2014-01754, 09-25-0099, 140157, 14-C-0157_9577, 14-C-0157, NCT02203526
Effects of STM 434 Alone or in Combination With Liposomal Doxorubicin in Patients With Ovarian Cancer or Other Advanced Solid Tumors
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: STM-434-001, NCI-2015-01111, NCI-2015-01109, NCT02262455
Pomalidomide and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Advanced or Refractory Kaposi Sarcoma
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 16-C-0047, NCI-2016-00067, P152279, NCT02659930
Start Over